Почетна › Немалоклетни карцином плућа › Оклахома
Kliničke studije za Немалоклетни карцином плућа u državi Оклахома
35 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Оклахома.
Gradovi u državi Оклахома
Zvanični tekst studije (na engleskom)
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Mercy Coletta Cancer Center, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07488676Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635BostonGene and Exigent Genomic INsight Study
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06272864Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06312137Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07388524Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Oklahoma City, Oklahoma City
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07857616Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT03191149FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- OU Health Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06720987Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316Study of XB010 in Subjects With Solid Tumors
- Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06545331Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- OU Health Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07807345A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0418, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07361510KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- OU Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06026410Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 2
18 Minutes · Оба пола · Ажурирано 9. 10. 2026. · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616584The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750Pan-tumor MRD Study
- Oklahoma Cancer Specialists and Research Institute (OCSRI), Tulsa
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06605404Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT06128551Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06767514A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06253871Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT06500481Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 7. 2026. · NCT06686771A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 6. 7. 2026. · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT07327489Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 6. 2026. · NCT05642572Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 5. 2026. · NCT05431270GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 5. 2. 2026. · NCT05236114A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 7. 1. 2026. · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2025. · NCT05107674Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.